黄葵胶囊联合缬沙坦标准化治疗糖尿病肾病的效果

Standardization of Sunflower Capsules and Valsartan in Treating Diabetic Nephropathy

目的:探究黄葵胶囊联合缬沙坦标准化治疗糖尿病肾病的效果。方法:选择糖尿病肾病60例患者(2021年1月至2021年10月),采用随机数字表法分组,每组30例。对照组给予缬沙坦治疗30例,试验组给予缬沙坦联合黄葵胶囊治疗30例。比较肾功能、炎症因子。结果:与治疗前比较,两组BUN、Scr、UAER水平下降(P<0.05);组间相比试验组比对照组低(P<0.05)。与治疗前比较,两组hs-CRP与TNF-α水平均降低(P<0.05);试验组比对照组水平低(P<0.05)。结论:对糖尿病肾病患者采取黄葵胶囊联合缬沙坦标准化治疗方案,能够显著改善肾功能、炎症因子。

Objective: To explore the effect of sunflower capsule and valsartan in standardized treatment of diabetic nephropathy. Methods: 60 patients with diabetic nephropathy(from January 2021 to October 2021) were selected and divided into the control group and the test group, with 30 patients in each group. The control group received valsartan,and the test group received valsartan with sunflower capsules. Renal function and inflammatory factors were compared.Results: BUN, Scr and B UAER decreased in both groups(P<0.05);the test group was lower than the control group(P<0.05). Compared with pre-treatment, hs-CRP and TNF-levels decreased(P<0.05), and the test group were lower than the control group(P<0.05). Conclusion: The adoption of sunfl ower capsule and valsartan in standardized treatment of diabetic nephropathy can signifi cantly improve renal function and inflammatory factors.